Actively Recruiting
Phase III Study to Compare Safety and Immune Response of MG1111 and Varivax Vaccines in Healthy Children Aged 12 Months to 12 Years
Led by GC Biopharma Corp · Updated on 2026-04-17
474
Participants Needed
1
Research Sites
465 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying MG1111 BARYCELA Inj. to evaluate its safety and immune response in healthy children aged 12 months to 12 years, comparing it with the existing varicella vaccine, VARIVAX. This Phase III trial is randomized, double-blind, and active-controlled, aiming to assess whether MG1111 is not inferior to VARIVAX in protecting against chickenpox. Participants are healthy children without prior varicella infection or vaccination. The trial involves two doses of either MG1111 or VARIVAX, administered according to a set schedule. Participants will be monitored for 42 days after the second dose to measure immune response and safety, including any local or systemic side effects. The study also includes long-term follow-up for up to 10 years to observe any varicella infections occurring after vaccination. Participants will undergo monitoring for immune response by measuring the proportion who develop antibodies 42 days after the second vaccination. Safety is assessed by recording side effects during the week following each vaccination and any adverse events up to six months after the second dose. The long-term follow-up will track varicella infections over 10 years, ensuring comprehensive observation throughout the study period.
CONDITIONS
Brief Title
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Research Team
M
Minji Ko
S
Sujin Lee
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here